Novo cuts self-pay pen pricing to about $349 a month
Direct cash pricing for the branded semaglutide pen falls far below list, narrowing the gap compounded programmes have relied on since 2023.
Novo Nordisk reduced self-pay pricing for its semaglutide pens to around $349 a month through its direct channel, against a Wegovy list price near $1,349 and Ozempic near $998.
It does not make brand cheaper than compounded — the cheapest verified compounded routes still sit below $200 all-in — but the fourfold gap that circulated through 2024 no longer exists.
Any comparison anchored on list price now overstates the compounded advantage by a wide margin, and most published comparisons still are.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement or the clinical review behind a prescription.
Where a development moves a figure we publish, the change is recorded with its date on our methodology page rather than edited in silently.
How to verify this yourself
Regulatory claims should be checked against the agency rather than coverage of the agency. FDA publishes warning letters searchable by company name and a drug shortage database, both free and both more current than any summary.